A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients.
A double-blind comparative trial of loxapine and trifluoperazine was carried out in 57 acute and chronic schizophrenic patients. In both groups of patients loxapine proved to be equivalent in its effects to trifluoperazine and there were suggestions it might be rather more effective in chronic patients. Side-effects were similar with the two drugs but anticholinergic effects, excitement, dizziness and faintness occurred rather more commonly with loxapine. Laboratory tests, urine analysis, cardiovascular and ophthalmological investigations showed no significant abnormalities.
D000208:Acute Disease; D000328:Adult; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D008152:Loxapine / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D014268:Trifluoperazine / Q000009:adverse effects / Q000627:therapeutic use*
D003989:Dibenzoxazepines; D014268:Trifluoperazine; D008152:Loxapine